Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FGF401 + spartalizumab
- Development stage
- Unknown
- Lead developer
- Novartis
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
FGF401 + spartalizumab is an investigational **combination therapy** consisting of FGF401 (roblitinib), a potent and selective inhibitor of fibroblast growth factor receptor 4 (FGFR4), and spartalizumab (PDR001), a humanized monoclonal antibody that targets PD-1. The combination is being studied primarily in patients with **hepatocellular carcinoma (HCC)** and other solid tumors exhibiting **FGFR4/KLB** expression. FGF401 blocks the FGF19-FGFR4 pathway that drives tumor growth and survival in some cancers, while spartalizumab acts as an **immune checkpoint inhibitor** by preventing PD-1 interaction with its ligands (PD-L1, PD-L2), thereby promoting T-cell-mediated anticancer activity.
- Other names
- roblitinib + spartalizumabFGF401 + PDR001
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)FGFR4 (Fibroblast growth factor receptor 4)
Beyond the preview
Go deeper on FGF401 + spartalizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FGF401 + spartalizumab.